RxDoctor Payments Data

David Barnes, MD

Family Medicine · Monroe, LANPI 1063411056

Payments from drug & device makers

$10,797in general payments, 2019–2025

Across 535 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$1K
  • Pfizer$808
  • Merck$718
  • Novo Nordisk$666
  • Esperion Therapeutics, Inc.$605
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$10,778100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,797 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$39,665
Medicare patients
112
Services billed
1,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$76,793
JardianceEmpagliflozin22$23,536
TradjentaLinagliptin28$22,873
Repatha SureclickEvolocumab17$15,126
JanuviaSitagliptin Phosphate22$12,600
CreonLipase/Protease/Amylase11$7,825
Ezetimibe182$7,214
XareltoRivaroxaban11$6,135
PremarinEstrogens, Conjugated13$6,033
LivaloPitavastatin Calcium12$4,106
Rosuvastatin Calcium282$3,883
Jentadueto XrLinagliptin/Metformin Hcl11$2,257
Telmisartan53$2,087
Metoprolol Succinate143$1,540
Celecoxib36$1,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$808$82,826117 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto Xr$586$48,66661 claims
MerckJanuvia$718$12,60022 claims
AbbVieCreon, Synthroid$531$8,89627 claims
Johnson & JohnsonXarelto$114$6,13511 claims
Kowa Pharmaceuticals America, Inc.Livalo$336$4,10612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →